DENVER, Colorado, August 10, 2026
Palisade Bio, Inc. announced its second-quarter 2026 financial results and provided a business update highlighting the continued advancement of PALI-2108 into Phase 2 development for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). The company expects to enroll the first patient in the Phase 2 ASCENTRA-UC trial during the second half of 2026, with primary efficacy results anticipated in the second half of 2027. Palisade Bio also expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Phase 2 ASCENTRA-CD trial during the second half of 2026, with trial initiation targeted for the first quarter of 2027. PALI-2108 is being developed as a once-daily oral, locally activated PDE4 inhibitor prodrug designed to provide targeted activity in the lower gastrointestinal tract while potentially improving tolerability and convenience.
PALI-2108 Shows Encouraging Phase 1 Clinical Findings
Palisade Bio said results from the completed Phase 1 clinical trial provided a strong foundation for advancing PALI-2108 into Phase 2. Across the study, the investigational therapy demonstrated favorable safety and tolerability, sustained exposure of its active metabolite above the IC90 threshold, targeted distribution in the ileum and colon, and pharmacodynamic activity across inflammatory and fibrotic pathways. The trial included five patients with ulcerative colitis and five patients with fibrostenotic Crohn’s disease (FSCD). In the UC cohort, all five patients achieved clinical response, while two achieved clinical remission based on the Modified Mayo Score. In the FSCD cohort, PALI-2108 reduced the mean SES-CD score by approximately 47.5%, representing a 3.8-point improvement, while two of five patients achieved both endoscopic response and remission. Palisade Bio believes these findings support further evaluation of PALI-2108 in larger Phase 2 patient populations.
ASCENTRA-UC and ASCENTRA-CD Programs Move Forward
The company has received FDA clearance of the IND application for PALI-2108, allowing preparations to continue for the Phase 2 ASCENTRA-UC study. Enrollment of the first patient is expected in 2H 2026, with the primary efficacy readout projected for 2H 2027. In parallel, Palisade Bio is finalizing the design of ASCENTRA-CD, a Phase 2 trial evaluating PALI-2108 in Crohn’s disease, and expects to submit its IND during 2H 2026. The company is targeting commencement of the Crohn’s disease study in 1Q 2027, with a primary efficacy readout expected in early 2028. The development strategy is focused on PALI-2108’s ability to undergo targeted activation and localized delivery in the ileum and colon, potentially making the approach relevant to Crohn’s disease, which can affect multiple regions of the gastrointestinal tract. Additional PALI-2108 data are also expected to be presented at the ACG 2026 Annual Scientific Meeting and UEG Week 2026.
Palisade Bio Reports $125.2 Million Cash Position
Palisade Bio reported research and development expenses of $7.4 million for the second quarter of 2026, compared with $1.7 million in the same period of 2025, reflecting increased clinical operations, CMC activities, employee-related expenses and preclinical and translational research supporting PALI-2108. General and administrative expenses increased to $4.8 million, compared with $1.2 million in the prior-year quarter. The company recognized $0.5 million in license revenue associated with a milestone under its co-development and distribution agreement with Newsoara. Net loss was $10.6 million, or $0.05 per share, compared with a net loss of $2.8 million, or $0.58 per share, for the second quarter of 2025. As of June 30, 2026, Palisade Bio held $125.2 million in cash and cash equivalents and expects its existing resources to support operations through major clinical milestones, including the planned 2027 ASCENTRA-UC primary efficacy readout and the anticipated early 2028 ASCENTRA-CD readout. The continued advancement of PALI-2108 into Phase 2 represents a significant development milestone for Palisade Bio and could provide important clinical evidence for its targeted PDE4 approach in IBD.
Source: Palisade Bio press release



